# Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema

> **NCT02079688** · PHASE2 · COMPLETED · sponsor: **Sterna Biologicals GmbH & Co. KG** · enrollment: 25 (actual)

## Conditions studied

- Mild to Moderate Atopic Dermatitis

## Interventions

- **DRUG:** SB011, 2 % (Water/Oil/Water) emulsion of hgd40
- **DRUG:** Multiple W/O/W formulation, active ingredient-free vehicle

## Key facts

- **NCT ID:** NCT02079688
- **Lead sponsor:** Sterna Biologicals GmbH & Co. KG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2016-11
- **Final completion:** 2017-01
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2017-01-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02079688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02079688, "Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of the Topical Formulation SB011 Applied to Lesional Skin in Patients With Atopic Eczema". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02079688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*